Department of Molecular Medicine and Surgery, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.
PLoS One. 2010 Mar 1;5(3):e9472. doi: 10.1371/journal.pone.0009472.
Parathyroid adenomas constitute the most common entity in primary hyperparathyroidism, and although recent advances have been made regarding the underlying genetic cause of these lesions, very little data on epigenetic alterations in this tumour type exists. In this study, we have determined the levels of promoter methylation regarding the four tumour suppressor genes APC, RASSF1A, p16(INK4A) and RAR-beta in parathyroid adenomas. In addition, the levels of global methylation were assessed by analyzing LINE-1 repeats.
METHODOLOGY/PRINCIPAL FINDINGS: The sample collection consisted of 55 parathyroid tumours with known HRPT2 and/or MEN1 genotypes. Using Pyrosequencing analysis, we demonstrate APC promoter 1A and RASSF1A promoter hypermethylation in the majority of parathyroid tumours (71% and 98%, respectively). Using TaqMan qRT-PCR, all tumours analyzed displayed lower RASSF1A mRNA expression and higher levels of total APC mRNA than normal parathyroid, the latter of which was largely conferred by augmented APC 1B transcription levels. Hypermethylation of p16(INK4A) was demonstrated in a single adenoma, whereas RAR-beta hypermethylation was not observed in any sample. Moreover, based on LINE-1 analyses, parathyroid tumours exhibited global methylation levels within the range of non-neoplastic parathyroid tissues.
CONCLUSIONS/SIGNIFICANCE: The results demonstrate that APC and RASSF1A promoter hypermethylation are common events in parathyroid tumours. While RASSF1A mRNA levels were found downregulated in all tumours investigated, APC gene expression was retained through APC 1B mRNA levels. These findings suggest the involvement of the Ras signaling pathway in parathyroid tumorigenesis. Additionally, in contrast to most other human cancers, parathyroid tumours were not characterized by global hypomethylation, as parathyroid tumours exhibited LINE-1 methylation levels similar to that of normal parathyroid tissues.
甲状旁腺腺瘤是原发性甲状旁腺功能亢进症中最常见的实体瘤,尽管近年来在这些病变的潜在遗传原因方面取得了进展,但关于这种肿瘤类型的表观遗传改变的数据却很少。在这项研究中,我们确定了甲状旁腺腺瘤中四个肿瘤抑制基因 APC、RASSF1A、p16(INK4A)和 RAR-β的启动子甲基化水平。此外,通过分析 LINE-1 重复序列评估了整体甲基化水平。
方法/主要发现:样本采集包括 55 例已知 HRPT2 和/或 MEN1 基因型的甲状旁腺肿瘤。通过焦磷酸测序分析,我们证明了大多数甲状旁腺肿瘤中 APC 启动子 1A 和 RASSF1A 启动子过度甲基化(分别为 71%和 98%)。使用 TaqMan qRT-PCR,分析的所有肿瘤均显示出较低的 RASSF1A mRNA 表达和较高的总 APC mRNA 水平,后者主要归因于 APC 1B 转录水平的增加。单个腺瘤中证实了 p16(INK4A)的高甲基化,而在任何样本中均未观察到 RAR-β 高甲基化。此外,基于 LINE-1 分析,甲状旁腺肿瘤表现出与非肿瘤性甲状旁腺组织相似的全基因组甲基化水平。
结论/意义:结果表明,APC 和 RASSF1A 启动子甲基化是甲状旁腺肿瘤中的常见事件。虽然所有研究的肿瘤中均发现 RASSF1A mRNA 水平下调,但通过 APC 1B mRNA 水平保留了 APC 基因表达。这些发现表明 Ras 信号通路参与了甲状旁腺瘤的发生。此外,与大多数其他人类癌症不同,甲状旁腺肿瘤没有表现出全基因组低甲基化,因为甲状旁腺肿瘤的 LINE-1 甲基化水平与正常甲状旁腺组织相似。